Mateon Therapeutics, Inc. MATN
No live quote for MATN yet.
- Market cap
- 10.22M
- EPS (ttm)
- -0.534
- Shares out
- 26.54M
- P/E ratio
- -0.72
- Forward P/E
- -0.66
- Volume
- 90.80K
- Avg volume
- 150.51K
- Open
- 0.381
- Previous close
- 0.4175
- Beta
- 1.50
- Analysts
- Buy
- Price target
- 2.00
Key statistics
- Enterprise value
- -5.13M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.72M
- Total cash
- 16.28M
- Total debt
- 0
- Return on equity
- -63.23%
- Short % of float
- 2.50%
- 50-day average
- 0.38697
- 200-day average
- 0.54
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 26, 2017 | Maxim Group | init | — | Buy |
About Mateon Therapeutics, Inc.
Mateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating gastrointestinal neuroendocrine tumors. The company also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.
- Country
- United States
- Website
- mateon.com
News
Your note
Sign in to keep a note on MATN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 4.12% | 1,094,900 | 678.84K | Sep 29, 2016 |
| Vanguard Group, Inc. (The) | 2.97% | 787,313 | 488.13K | Sep 29, 2016 |
| GRT Capital Partners, LLC | 0.57% | 151,250 | 93.78K | Sep 29, 2016 |
| Geode Capital Management, LLC | 0.23% | 60,393 | 37.44K | Sep 29, 2016 |
| CALPERS (California-Public Employees Retirement System) | 0.19% | 51,107 | 31.69K | Sep 29, 2016 |
| Citadel Advisors LLC | 0.11% | 27,950 | 17.33K | Sep 29, 2016 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.31% | 348,782 | 244.15K | Jun 29, 2016 |
| Vanguard Total Stock Market Index Fund | 1.29% | 343,666 | 240.57K | Jun 29, 2016 |
| Vanguard Balanced Index Fund | 0.23% | 61,300 | 42.91K | Jun 29, 2016 |
| Fidelity Extended Market Index Fund | 0.21% | 55,832 | 37.41K | Aug 30, 2016 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.03% | 6,839 | 4.24K | Sep 29, 2016 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 4,000 | 2.68K | Aug 30, 2016 |